Specialty medical injectable drug program, requirements and drug policy updates: Skyrizi®
New specialty medical injectable updates and requirements announced.
Aug. 26, 2022
- Operations
- All states
- All Business Sizes
Please review the following table to determine changes to our specialty medical injectable drug programs.
| Drug Name | UnitedHealthcare Commercial | Treatment Uses |
|---|---|---|
| Skyrizi® (risankizumab-rzaa) |
X | New formulation and dosage, used to treat adults with moderate to severe Crohn’s disease. |
Review the UnitedHealthcare Commercial Plan Review at Launch Medication List.
For questions, please contact your broker or UnitedHealthcare representative.
More updates for your business
New releases, updates and notifications for a broad spectrum of UnitedHealthcare products and services.
Important, required notices for products, plans, forms and more.
Need-to-know operational announcements for you and your employees.